hrqol and efficacy in the phase iii persist-1 trial of pacritinib vs bat
Published 8 years ago • 172 plays • Length 6:49Download video MP4
Download video MP3
Similar videos
-
4:56
outcomes in patients with myelofibrosis: pacritinib vs. bat in the phase iii persist-1 trial
-
3:40
persist-1 phase iii study of pacritinib versus bat in pmf, ppv-mf, or pet-mf
-
3:46
results of the phase iii persist-1 trial of pacritinib for myelofibrosis
-
3:40
persist-1 phase iii study of pacritinib versus bat in pmf, ppv-mf, or pet-mf
-
4:28
results of the persist-2 phase 3 study of pacritinib (pac) versus...
-
1:45
design and results of pacritinib for myelofibrosis trial (persist-1)
-
1:42
consistency of pacritinib in patients with mf: pooled analysis from persist-1 & persist-2
-
2:03
results of the phase 3 persist-1 trial of pacritinib in myelofibrosis
-
1:45
results of the phase 3 persist-1 trial of pacritinib for myelofibrosis
-
4:07
safety of full dose pacritinib versus bat in patients with cytopenic myelofibrosis
-
3:21
emerging agents pacritinib and momelotinib for mf
-
1:11
pacritinib vs ruxolitinib
-
1:59
pacritinib versus ruxolitinib in patients with myelofibrosis and thrombocytopenia
-
1:46
the efficacy of pacritinib in patients with myelofibrosis who have both thrombocytopenia and anemia
-
3:35
new phase iii trial of imetelstat versus bat in jak inhibitor-refractory myelofibrosis
-
1:31
risk-adjusted safety analysis of pacritinib for patients with mf
-
4:12
pacritinib for patients with mf across the cytopenic spectrum
-
4:49
hrqol of pembrolizumab vs. chemotherapy for previously treated...
-
4:38
does the patient with myelofibrosis feel better through pacritinib?